Monika K Krzyzanowska
Affiliation: University of Toronto
- Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancerMonika K Krzyzanowska
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Ontario, Canada
J Am Coll Surg 208:202-9. 2009..To study surgeons' versus oncologists' preferences for adjuvant chemotherapy for elderly patients with stage III colon cancer, as population studies indicate that such patients are less likely to receive treatment...
- Identifying population-level indicators to measure the quality of cancer care for womenMonika K Krzyzanowska
Department of Medicine, University of Toronto, Toronto, Canada
Int J Qual Health Care 23:554-64. 2011..The objective of this study was to identify a comprehensive set of quality indicators for evaluation of the quality of cancer care received by women using administrative data...
- A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinomaMonika K Krzyzanowska
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Cancer Chemother Pharmacol 60:135-41. 2007..The lack of effective systemic therapies for patients with advanced renal cell carcinoma (RCC) has stimulated interest in evaluating novel treatment strategies for this disease...
- Using economic analysis to evaluate the potential of multimodality therapy for elderly patients with locally advanced pancreatic cancerMonika K Krzyzanowska
Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA, USA
Int J Radiat Oncol Biol Phys 67:211-8. 2007..Economic modeling can be used to explore the potential of such novel therapies and to inform clinical trial design...
- Potential drug interactions in cancer patients receiving supportive care exclusivelyRachel P Riechelmann
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
J Pain Symptom Manage 35:535-43. 2008..Older patients, those with comorbid conditions, brain tumor patients, and those taking many medications are at greater risk of drug interactions...
- Determinants of quality of life in patients with advanced cancerCamilla Zimmermann
Division of Medical Oncology and Hematology, Department of Medicine, Toronto, Canada
Support Care Cancer 19:621-9. 2011..Improving health-related quality of life (HRQL) is the main goal of palliative care and an important outcome for oncology trials. This study examines medical and sociodemographic determinants of HRQL in outpatients with advanced cancer...
- Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetingsPhilippe L Bedard
Division of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, Ontario, Canada
J Clin Oncol 25:3482-7. 2007..To investigate the prevalence of underpowered randomized controlled trials (RCTs) presented at American Society of Clinical Oncology (ASCO) annual meetings...
- Referral practices of oncologists to specialized palliative careKirsten Wentlandt
University of Toronto, Toronto, Ontario, Canada
J Clin Oncol 30:4380-6. 2012..To describe current referral practices of oncologists to specialized palliative care (SPC) and define demographic characteristics, practice situations, and opinions associated with referral...
- Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic reviewLinda Lee
Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
J Clin Oncol 29:106-17. 2011..Abstracts were reviewed for eligibility, and data on study design and results were extracted...
- Quality of abstracts describing randomized trials in the proceedings of American Society of Clinical Oncology meetings: guidelines for improved reportingMonika K Krzyzanowska
Department of Medical Oncology, Princess Margaret Hospital, University of Toronto, ON, Canada
J Clin Oncol 22:1993-9. 2004....
- Potential drug interactions and duplicate prescriptions among cancer patientsRachel P Riechelmann
Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Ave, Toronto, ON, M5G 2M9, Canada
J Natl Cancer Inst 99:592-600. 2007..Cancer patients receive numerous medications, including antineoplastic agents, drugs for supportive care, and medications for comorbid illnesses. Therefore, they are at risk for drug interactions and duplicate prescribing...
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancerDaniel J Renouf
University Health Network Princess Margaret Hospital, Toronto, ON, Canada
Invest New Drugs 30:1203-7. 2012..This phase II study of eribulin in patients with advanced pancreatic cancer previously treated with gemcitabine was conducted by the Princess Margaret Hospital Phase II consortium...
- Relationships between authorship contributions and authors' industry financial ties among oncology clinical trialsSusannah L Rose
Department of Health Care Policy, Harvard Medical School, Dana Farber Cancer Institute, Boston, MA 02115, USA
J Clin Oncol 28:1316-21. 2010..CONCLUSION Authors who perform key roles in the conception and design, analysis, and interpretation, or reporting of oncology clinical trials are more likely than authors who do not perform such roles to have financial ties to industry...
- Bereavement practices of physicians in oncology and palliative careNicole G Chau
Princess Margaret Hospital, Department of Medical Oncology and Hematology, University of Toronto, Toronto, ON M5G 2M9, Canada
Arch Intern Med 169:963-71. 2009....
- Evolution of the randomized controlled trial in oncology over three decadesChristopher M Booth
National Cancer Institute of Canada Clinical Trials Group, Queen s University, Kingston, Ontario, Canada
J Clin Oncol 26:5458-64. 2008..The randomized controlled trial (RCT) is the gold standard for establishing new therapies in clinical oncology. Here we document changes with time in design, sponsorship, and outcomes of oncology RCTs...
- Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective studyThomas Walter
Princess Margaret Hospital, Toronto, Ontario, Canada
Eur J Cancer 49:329-35. 2013..First-line chemotherapy (CT1) is effective in advanced biliary tract cancer (ABTC). The benefits of second-line chemotherapy (CT2) are unclear...
- Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectivenessMonika K Krzyzanowska
Center for Outcomes and Policy Research, Dana Farber Cancer Institute, 44 Binney St, 454 STE 21 24, Boston, MA 02115, USA
J Clin Oncol 21:3409-14. 2003..To evaluate the use and effectiveness of cancer-directed therapy in elderly patients with locally advanced pancreatic cancer (LAPC)...
- Compendium of unpublished phase III trials in oncology: characteristics and impact on clinical practiceVincent C Tam
Princess Margaret Hospital, 610 University Ave, Ste 5 206, Toronto, Ontario, Canada M5G 2M9
J Clin Oncol 29:3133-9. 2011..Many phase III trials presented at annual meetings of the American Society of Clinical Oncology (ASCO) remain unpublished. The results of these unpublished trials, if more generally known, might have an impact on clinical practice...
- A survey of abstracts of high-impact clinical journals indicated most statistical methods presented are summary statisticsNathan Taback
Centre for Research on Inner City Health, The Keenan Research Centre in the Li Ka Shing Knowledge, Institute of St Michael s Hospital, 30 Bond Street, Toronto, Ontario, Canada M5B 1W8
J Clin Epidemiol 61:277-81. 2008..To assess what statistical methods are commonly used in high-impact clinical research and how they are presented in abstracts of articles published in high-impact medical journals...
- Quality of clinical trials in gastroenteropancreatic neuroendocrine tumoursThomas Walter
Department of Medical Oncology and Hematology, Princess Margaret Hospital, Toronto, ON, Canada
Neuroendocrinology 96:238-48. 2012..Our aim was to review the quality of treatment trials in NETs in order to inform the design and reporting of future studies...
- What do oncologists want? Suggestions from oncologists on how their institutions can support them in dealing with patient lossLeeat Granek
Department of Psychology, Hospital for Sick Children, Toronto, Ontario, Canada
Support Care Cancer 20:2627-32. 2012..The purpose of the study was to explore what institutional support(s) oncologists want to help them cope with patient loss...
- Symptom and medication profiles among cancer patients attending a palliative care clinicRachel P Riechelmann
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, ON, Canada
Support Care Cancer 15:1407-12. 2007..We describe the symptomatology and medication profile of ambulatory cancer patients receiving exclusively supportive care at the Princess Margaret Hospital...
- Adherence to surveillance guidelines after curative resection for stage II/III colorectal cancerWinson Y Cheung
Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Ontario, Canada
Clin Colorectal Cancer 7:191-6. 2008....
- Factors associated with failure to publish large randomized trials presented at an oncology meetingMonika K Krzyzanowska
Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Mass, USA
JAMA 290:495-501. 2003..Large clinical trials are the criterion standard for making treatment decisions, and nonpublication of the results of such trials can lead to bias in the literature and contribute to inappropriate medical decisions...
- American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancerAl B Benson
American Society of Clinical Oncology, Alexandria, VA 22314, USA
J Clin Oncol 22:3408-19. 2004....